Chikungunya in depth.
Named from the Kimakonde language meaning "that which bends up" — chikungunya's crippling joint pain can persist for months to years, disabling millions across tropical regions.
Overview
Chikungunya is a mosquito-borne viral disease best known for causing debilitating joint pain. Caused by Chikungunya virus (CHIKV, Togaviridae), it spreads through the bite of infected Aedes aegypti or Aedes albopictus mosquitoes. Key symptoms: sudden fever, severe polyarthralgia (joint pain), muscle pain, and rash. While rarely fatal (CFR <0.1%), joint pain may persist for months or years in some patients.
Chikungunya is rarely fatal (<1% CFR) but causes intense suffering. The combination of high fever and severe, often symmetric arthralgia (joint pain) affecting multiple joints — particularly wrists, ankles, elbows, knees, and hands — can be completely debilitating. In 30–40% of cases, chronic arthritis persists for months to years after the acute infection resolves.
Historically endemic in Africa and Asia, chikungunya has expanded globally since 2004. The 2005–2006 Indian Ocean epidemic was the first major outbreak — infecting an estimated 40% of the population of Réunion (270,000 cases) and spreading to India (1.5+ million cases). The 2013–2015 Caribbean and Americas outbreak brought chikungunya to the New World for the first time. In 2023, Brazil experienced its largest ever chikungunya outbreak. In 2024, the first locally acquired case in continental Europe (Italy, France) added to concerns about the disease's expanding footprint driven by climate change extending Aedes albopictus range.
Transmission
- Primary vectors: Aedes aegypti (tropical urban environments) and Aedes albopictus (Asian tiger mosquito, more cold-tolerant — enabling spread to temperate regions including Europe)
- Mosquitoes become infected by biting a viremic person during the acute illness (days 1–5 typically)
- Not directly contagious between people — requires a mosquito vector
- Rare: vertical (mother-to-child) transmission at delivery documented; blood transfusion and organ transplantation transmission possible but rare
Symptom Timeline
Incubation: 1–12 days (most commonly 3–7 days).
- Abrupt onset of high fever (39–40°C)
- Severe symmetric polyarthralgia — joint pain affecting multiple joints simultaneously, often migratory
- Joints most commonly affected: wrists, ankles, fingers, toes, knees, elbows, shoulders
- Joint swelling and morning stiffness
- Maculopapular rash (trunk, limbs) — develops in 40–50% of patients
- Headache, myalgia, fatigue
- Conjunctival injection; mild photophobia
- Fever typically resolves within 2–7 days
- Joint pain may intensify after fever resolves — classically described as the most severe after fever breaks
- Rash fades; fatigue persists
- Most patients improve significantly within 2–3 weeks of acute illness
- 30–40% of patients develop chronic arthritis lasting 3 months to >3 years
- Symmetric polyarthritis — can mimic rheumatoid arthritis; RF and anti-CCP antibodies may be transiently positive
- Older age, pre-existing joint disease, and severe acute arthralgia predict chronic disease
- Chronic fatigue, depression, reduced quality of life
Diagnosis
- RT-PCR: Gold standard in the first 5–7 days of illness (during viraemia). Highly sensitive and specific. Identifies CHIKV RNA in blood.
- IgM/IgG ELISA: IgM appears from day 5–7, peaks at 3–5 weeks. Useful for diagnosis after the viraemic phase. IgG indicates past infection.
- Rapid antigen tests: Some rapid tests available; sensitivity lower than PCR.
- Differential diagnosis: Dengue, Zika, and chikungunya co-circulate in same areas and share mosquito vectors. Severe symmetric joint pain strongly favours chikungunya. Thrombocytopenia more typical of dengue; congenital abnormalities more typical of Zika.
Treatment
No specific antiviral treatment for chikungunya exists. Management is symptomatic.
- NSAIDs (ibuprofen, naproxen): First-line for arthralgia after dengue has been ruled out. Effective for joint pain reduction. Note: NSAIDs are contraindicated in dengue — so diagnosis must be clarified first.
- Paracetamol: Use for fever; first choice until dengue is excluded.
- Chloroquine: Some evidence for benefit in chronic post-chikungunya arthritis in endemic settings; mixed evidence in controlled trials.
- Methotrexate: Used for severe chronic arthritis resembling rheumatoid arthritis; specialist referral required.
- Corticosteroids: Low-dose short-course for severe acute arthritis; risk of rebound flare on discontinuation.
- Rest and physiotherapy: Gentle movement exercises and physiotherapy in the chronic phase help restore joint function and reduce disability.
Prevention & Vaccine
- IXCHIQ (VLA1553, Valneva): FDA-approved single-dose live attenuated chikungunya vaccine (November 2023) for adults ≥18 years at elevated risk of exposure. First and only approved chikungunya vaccine. ~98% seroconversion rate in trials; 1-year protection data robust. EU conditional marketing authorisation granted 2024.
- Personal protection: DEET repellents; permethrin-treated clothing; long-sleeved clothing and trousers; window/door screens; eliminating standing water breeding sites.
- Vector control: Larval control (eliminating standing water containers), adult mosquito control (insecticide spraying), community-level awareness.
- Travel advice: Travellers to chikungunya-endemic regions should consider IXCHIQ vaccine >4 weeks before travel; use EPA-approved mosquito repellents.
Global Impact
Chikungunya has infected an estimated 3–4 million people annually in recent years, with 2023–2024 seeing record outbreaks in Brazil (300,000+ cases and 150+ deaths in early 2024 alone), Paraguay, and other Latin American countries. The economic burden of chikungunya is enormous — primarily from lost productivity due to debilitating chronic joint pain affecting working-age adults.
Climate change is expanding the range of Aedes albopictus into previously cool regions of Europe and North America, raising the risk of locally acquired chikungunya outside the tropics. The 2007 Italy outbreak (200+ locally acquired cases) and 2014 France cases are examples of this trend. The first FDA-approved vaccine (IXCHIQ, 2023) represents a major advance, though mass vaccination programmes in endemic regions remain limited by cost and supply.
History & Major Outbreaks
Chikungunya virus was first isolated in 1952 during an outbreak in Tanzania (then Tanganyika), near the Makonde Plateau — giving rise to its name in the local Kimakonde language. Early outbreaks were documented in Uganda (1963), Zimbabwe (1969), and Senegal (1966), but the disease remained relatively obscure until the 2000s.
A key evolutionary event occurred around 2006: a single mutation in the E1 envelope protein (A226V) enabled CHIKV to replicate efficiently in Aedes albopictus, whose cold-tolerance allowed the virus to spread from the Indian Ocean islands into Italy, France, and temperate Europe. The 2005–2006 Indian Ocean epidemic — centered on Réunion (270,000 cases), Mauritius, and India (1.5+ million cases) — was the first global alert. The 2007 Castiglione di Cervia outbreak in Italy (197 locally acquired cases) proved CHIKV could establish autochthonous transmission in Europe.
- 2005–2006: Indian Ocean islands and India — >1.5 million cases; first international pandemic-scale chikungunya event
- 2007: Italy — first autochthonous European outbreak (Aedes albopictus vector)
- 2013–2015: Caribbean and Americas — chikungunya reaches the Western Hemisphere for the first time; >1 million cases across 45 territories and countries
- 2016: Brazil — 265,000+ reported cases; joins dengue and Zika as co-circulating threat
- 2023: Brazil — 313,000+ cases; Paraguay, Bolivia also record outbreaks
- 2024: Brazil — record outbreak exceeding 300,000+ cases in H1 2024; first IXCHIQ vaccine deployments in some settings
Virology & Pathophysiology
Chikungunya virus is a single-stranded, positive-sense RNA virus of the genus Alphavirus (family Togaviridae). The genome (~11.8 kb) encodes four non-structural proteins (nsP1–4) responsible for RNA replication, and five structural proteins: capsid (C), and envelope glycoproteins E1, E2, E3, and 6K. The E2 protein mediates receptor binding; E1 contains the fusion peptide required for cell entry.
Pathogenesis: After inoculation by an Aedes mosquito, CHIKV replicates locally in dermal fibroblasts and epithelial cells, triggering an innate immune response with type-I interferons. Viremia peaks within the first 3–5 days and disseminates virus to target tissues including muscle, joints, liver, and the central nervous system. CHIKV displays particular tropism for synovial macrophages and fibroblasts, which drives the characteristic severe and persistent arthritis. In the joints, virus triggers a pro-inflammatory macrophage response with IL-1β, TNF-α, and IL-6, causing synovitis and cartilage damage. Chronic arthritis may result from viral persistence in joint tissues and/or self-perpetuating autoimmune mechanisms even after viral clearance.
Risk Factors & Special Populations
- Age: Neonates and infants born to viremic mothers — risk of severe neonatal chikungunya including encephalopathy, myocarditis, skin lesions; mortality ~10% in neonatal cases
- Elderly (>65 years): Markedly higher risk of severe disease, neurological complications, and chronic post-chikungunya arthritis
- Pre-existing joint disease: Rheumatoid arthritis, osteoarthritis — significantly worsens prognosis for chronic post-infection arthritis
- Immunocompromised: HIV, organ transplant recipients — more severe acute disease; limited data on chronic outcomes
- Travellers: Adults with no prior CHIKV exposure who travel to endemic regions and those living near Aedes albopictus populations in non-endemic temperate regions
- Healthcare workers: Risk of nosocomial transmission through needlestick from viremic patients; exposure to infected tissue samples
- Pregnant women: Vertical transmission documented at delivery when mother is viremic; risk of neonatal chikungunya estimated at 50% when mother is viremic at delivery
Complications
Neurological
- Encephalitis and encephalopathy — more common in elderly and neonates
- Guillain-Barré syndrome (rare but documented)
- Peripheral neuropathy, myelopathy
- Cerebellar ataxia, myeloradiculopathy
Cardiovascular
- Myocarditis (uncommon; more severe in elderly)
- Arrhythmias, pericarditis
- Acute heart failure in severe cases
Ophthalmic
- Uveitis, iridocyclitis, retinitis
- Optic neuritis (rare)
Rheumatological (Chronic Post-Chikungunya Arthritis)
- Chronic symmetric polyarthritis — identical in presentation to rheumatoid arthritis in many cases
- Occurs in 30–40% of patients; can persist for 2–3+ years
- MRI may show synovitis, joint effusions, tenosynovitis
- RF and anti-CCP may be transiently positive, complicating diagnosis
- Standard rheumatoid arthritis treatments (NSAIDs, hydroxychloroquine, methotrexate) are used for management
Chikungunya vs Dengue vs Zika: Comparison
| Feature | Chikungunya | Dengue | Zika |
|---|---|---|---|
| Pathogen | CHIKV (Alphavirus) | DENV 1-4 (Flavivirus) | ZIKV (Flavivirus) |
| Vector | Ae. aegypti & albopictus | Primarily Ae. aegypti | Ae. aegypti (+ sexual) |
| Fever | High (39–40°C), abrupt | High, biphasic | Low-grade or absent (80% subclinical) |
| Hallmark symptom | Severe crippling joint pain | Thrombocytopenia, plasma leakage | Congenital microcephaly |
| Rash | Common (maculopapular) | Common (later phase) | Common (diffuse, pruritic) |
| Mortality | <1% (complications) | 0.5–5% (severe dengue) | Very rare in adults |
| Key concern | Chronic arthritis (years) | DHF, shock syndrome | Fetal harm (microcephaly, GBS) |
| NSAIDs | Useful for arthralgia | CONTRAINDICATED | Generally ok (after dengue excluded) |
| Vaccine | IXCHIQ (2023, FDA) | Dengvaxia; Qdenga | None approved |
Research & Pipeline
Following the FDA approval of IXCHIQ (Valneva, November 2023), several other chikungunya vaccine candidates are in development:
- mRNA-1944 (Moderna): mRNA vaccine candidate in Phase 1/2 trials; leverages mRNA platform validated by COVID-19 vaccines
- BBV87 (Bharat Biotech): Inactivated chikungunya vaccine candidate in development in India for endemic populations
- Antivirals: No approved antivirals exist; ribavirin, chloroquine, and various monoclonal antibodies have been studied with limited success; ongoing research into CHIKV nsP2 helicase and E2 protein as drug targets
- Wolbachia mosquito releases: Wolbachia-infected Aedes aegypti (shown to reduce dengue transmission) may also suppress chikungunya and Zika transmission — trials ongoing in several countries
Country-Specific Information
Frequently Asked Questions
Sources & Citations
When to Seek Emergency Care
Most chikungunya is managed at home. Seek emergency care immediately if any of the following appear:
- High fever unresponsive to paracetamol after 3 days
- Confusion, altered consciousness, or seizures
- Difficulty breathing or chest pain
- Bleeding from any site
- Signs of shock: cold skin, rapid weak pulse, very low blood pressure
- Inability to stand or walk due to joint pain
- Newborn with fever and rash (neonatal chikungunya emergency)
- Skin lesions turning dark or gangrenous
Climate Change & Geographic Expansion
The range of Aedes albopictus — chikungunya's "cold-tolerant" vector — is expanding northward due to climate warming. Regions newly at risk include:
- Southern Europe: Italy, Spain, France, Greece, Portugal — Aedes albopictus well-established; local chikungunya transmission events already documented (Italy 2007, 2017; France 2014, 2022)
- Central Europe: Germany, Austria, Switzerland — Aedes albopictus spreading northward; first confirmed overwintering populations in Germany 2023
- Eastern USA: Aedes albopictus established across the Southeast and Mid-Atlantic; Florida, Georgia, North Carolina at rising risk
- Higher altitudes: Climate change expanding the elevation range of Aedes mosquitoes in India, Latin America, East Africa
Climate models project a 400–600% increase in the population at risk of chikungunya by 2080 under high-emission scenarios, primarily through Aedes albopictus range expansion into temperate regions that currently have no endemic transmission.
Self-Care & Living with Post-Chikungunya Arthritis
- Exercise therapy: Gentle range-of-motion exercises (swimming, yoga, stretching) reduce joint stiffness without overloading inflamed joints; avoid high-impact activities during flares
- Heat vs cold: Warm compresses or warm water soaks reduce morning stiffness; cold packs can relieve acute joint swelling and pain
- NSAIDs for chronic arthritis: Ibuprofen or naproxen with food; use lowest effective dose; monitor renal function and GI tolerance; always exclude dengue first in endemic areas
- Hydroxychloroquine: Antimalarial with anti-inflammatory properties; used in refractory post-chikungunya arthritis; monitor for ocular toxicity with long-term use
- Occupational therapy: Joint protection techniques; assistive devices for activities of daily living; particularly important for elderly patients
- Mental health support: Chronic pain and disability from chikungunya arthritis is associated with depression and anxiety; psychosocial support improves outcomes
- Follow-up: Rheumatology referral for patients with persistent arthritis >3 months; MRI can assess synovial inflammation and guide treatment decisions
Related Diseases
Key Terms: Chikungunya
- CHIKV: Chikungunya virus — the causative Alphavirus of chikungunya disease
- Arthralgia: Joint pain — the hallmark symptom of chikungunya, often severe and symmetric
- Polyarthralgia: Pain affecting multiple joints simultaneously
- Aedes albopictus: The Asian tiger mosquito — secondary vector of CHIKV and increasingly dominant in temperate regions due to climate change
- Post-chikungunya arthritis: Persistent joint inflammation lasting >3 months after acute chikungunya; occurs in 30-40% of patients
- IXCHIQ: The first FDA-approved chikungunya vaccine (Valneva, 2023); single-dose live attenuated vaccine for adults ≥18 years
- E1 protein: Envelope glycoprotein of CHIKV; the A226V mutation in E1 enabled efficient Aedes albopictus transmission, enabling the 2005-2006 Indian Ocean epidemic
- Viremia: Presence of virus in the blood; the window during which a mosquito can acquire CHIKV from a bitten person (days 1-5)
- Togaviridae: Viral family containing chikungunya virus (Alphavirus genus)
- Seroconversion: Development of detectable antibodies in blood — indicates successful immune response to infection or vaccination
More Chikungunya Questions
Epidemiology at a Glance: Chikungunya
| Region | Burden | Notes |
|---|---|---|
| Africa (Sub-Saharan) | Endemic; major outbreaks in Tanzania, Kenya, Comoros, Reunion, Mauritius | Origin region; cyclical outbreaks; 2005-2006 Indian Ocean epidemic epicenter |
| South Asia | India: millions in 2006 & 2016; Sri Lanka, Bangladesh, Pakistan, Maldives | India had 1.5M+ cases in 2006; major burden in urban areas |
| Southeast Asia | Philippines, Indonesia, Malaysia, Thailand, Myanmar — endemic | Co-circulates with dengue; often under-diagnosed as dengue |
| Americas | >4M cases 2013–2016 (first introduction); Brazil 300K+ in 2024 | Introduced 2013 via Caribbean; now firmly established in Americas |
| Europe | Sporadic local outbreaks: Italy 2007, 2017; France 2014, 2022 | Via Aedes albopictus; climate change driving northward expansion |
| Global total (estimated) | ~3.8 million cases/year | Significant underreporting; true burden may be 10–50× reported figures |
Reported cases represent a small fraction of true burden due to mild illness, limited diagnostics, and underreporting in resource-limited settings.
Chikungunya Prevention Checklist
- Use insect repellent: Apply DEET (30%+), picaridin, or OLE repellent to all exposed skin. Reapply every 2-4 hours and after sweating or swimming
- Cover up: Wear light-coloured long-sleeved shirts and long trousers, especially during peak Aedes biting hours (2 hours after sunrise; 2 hours before sunset)
- Eliminate breeding sites: Empty, turn over, or cover any water-holding containers around your home (flower pots, buckets, tyres, cans, clogged gutters, bird baths) at least weekly
- Screen windows and doors: Use wire mesh screens; keep air conditioning on if available (Aedes mosquitoes do not tolerate cold)
- Sleep protection: Use a bed net even during daytime naps if in a highly endemic area
- Permethrin-treated clothing: Spray or soak outdoor clothing with permethrin (do NOT apply to skin); provides protection for multiple washes
- Consider IXCHIQ vaccine: Adults ≥18 traveling to endemic regions or living in active outbreak areas should discuss the single-dose IXCHIQ vaccine with their doctor at least 4 weeks before travel
- Community participation: Report standing water and mosquito breeding hotspots to local health authorities; participate in community clean-up campaigns
Chikungunya: Quick Clinical Reference
Get Outbreak Alerts
regularly updated infectious disease outbreak notifications, delivered free to your inbox.
Global Surveillance & Reporting
Chikungunya surveillance relies on national health ministries reporting to WHO and PAHO. Under-reporting is endemic to tropical regions with limited laboratory infrastructure. The ECDC maintains a dedicated surveillance portal tracking European imported cases. Key surveillance challenges include:
- Cross-reactivity: Serological tests cross-react with other alphaviruses and flaviviruses
- Asymptomatic cases: Estimated 15–20% of infections produce no fever, escaping detection
- Passive surveillance: Most countries rely on clinician-initiated reporting rather than active case-finding
- Dual epidemics: Co-circulation with dengue causes frequent misclassification in field settings
Climate Change & Vector Expansion
Rising temperatures and shifting rainfall patterns are expanding the geographic range of Aedes albopictus (tiger mosquito) into previously temperate zones. Southern Europe, northern China, and parts of North America are now considered at risk. The 2007 Italian outbreak (>200 cases) was the first documented chikungunya transmission in a temperate European country and was enabled entirely by established Ae. albopictus populations.
Climate models project that by 2050, an additional 1.3 billion people will live in areas where chikungunya transmission is climatically feasible, assuming no significant vector control advances.
Traveler Guidance
Travelers to tropical and subtropical regions should:
- Apply DEET-based or picaridin repellent every 4–6 hours, especially at dawn and dusk
- Wear light-colored, long-sleeved clothing
- Use air conditioning or permethrin-treated bed nets
- Seek care within 72 hours of fever onset — RT-PCR is only reliable in the first week
- Avoid aspirin and NSAIDs until dengue is ruled out (bleeding risk)
No travel restrictions are in place for chikungunya-endemic areas; the CDC and WHO classify it as a travel health notice requiring routine precautions only.
Additional Frequently Asked Questions
- Can chikungunya be transmitted sexually or through blood transfusion?
- Sexual transmission has not been documented. Blood transfusion risk exists during viremic phase (first 3–5 days of illness); most blood banks in endemic regions screen donors for fever history. Vertical transmission (mother-to-child) during delivery has been reported and can cause severe neonatal disease including encephalopathy.
- Is there a cure for chronic chikungunya arthritis?
- No specific cure exists. Management focuses on symptom control with analgesics, NSAIDs (after dengue exclusion), and physiotherapy. Hydroxychloroquine has shown benefit in some case series for prolonged inflammatory arthritis lasting more than 3 months. Most patients improve significantly within 12–18 months even without treatment.
- Can children get chikungunya?
- Yes. Children generally experience milder disease than adults. However, neonates born to viremic mothers and infants under 1 year face higher risk of severe disease including encephalitis. School-age children rarely develop chronic arthritis — that complication predominantly affects adults over 45.
- How is chikungunya different from dengue in treatment?
- The key practical difference: dengue carries bleeding risk, so aspirin and NSAIDs are contraindicated until dengue is ruled out. For chikungunya (once dengue is excluded), NSAIDs are first-line for joint pain. Both diseases have no specific antiviral — supportive care is the mainstay for both.
Key Statistics at a Glance
| Metric | Value |
|---|---|
| Global endemic countries | 110+ |
| Annual estimated cases | 1–4 million |
| Case fatality rate | <1% (higher in elderly/neonates) |
| Chronic arthritis risk | 30–40% of survivors (lasting months to years) |
| Incubation period | 2–12 days (typically 3–7 days) |
| Mosquito vectors | Aedes aegypti, Aedes albopictus |
| Vaccine status (2025) | Ixchiq (live-attenuated, FDA 2023) — adults 18+ only |
| Antiviral treatment | None approved; supportive care only |
Differential Diagnosis
Chikungunya is frequently confused with other febrile illnesses. Key distinguishing features for clinicians:
- vs Dengue: Chikungunya arthralgia is typically more severe, symmetric, and persists longer; dengue more often causes thrombocytopenia, retro-orbital pain, and hemorrhagic features
- vs Zika: Zika presents with milder fever, prominent conjunctivitis, and maculopapular rash; chikungunya arthralgia is more disabling; Zika linked to microcephaly and GBS
- vs Rheumatoid Arthritis: Chikungunya arthritis onset is acute with fever; rheumatoid is insidious; anti-CCP antibodies positive in RA, negative in chikungunya
- vs Leptospirosis: Leptospirosis linked to water/soil exposure; jaundice and renal impairment more common; chikungunya rash and joint pattern distinctive
In areas of co-circulation, multiplex PCR panels that simultaneously test for dengue, chikungunya, and Zika are the most efficient diagnostic approach.
Medical Information Notice
This page is produced by the VirusWatch Editorial Team and reviewed against peer-reviewed medical literature and official guidance from WHO, CDC, ECDC, and national health authorities. Information reflects the state of scientific knowledge at the publication date and is updated regularly.
VirusWatch content is for public health education only and does not constitute medical advice, diagnosis, or treatment recommendations. If you have symptoms of any disease described on this site, consult a qualified healthcare provider promptly. Do not delay seeking professional medical care based on information read here.
For health emergencies, contact your local emergency services or go to the nearest emergency department.
Sources & Further Reading
- World Health Organization (WHO) — global disease surveillance and guidelines
- US Centers for Disease Control and Prevention (CDC) — US public health guidance and travel advisories
- European Centre for Disease Prevention and Control (ECDC) — European surveillance and risk assessments
- PubMed / MEDLINE — peer-reviewed medical literature
- The Lancet — leading medical journal with comprehensive outbreak reporting
- New England Journal of Medicine (NEJM) — clinical research and outbreak investigations
Frequently Asked Questions: Travel & Return
- If I had chikungunya years ago, am I still protected?
- Yes. A single infection with chikungunya typically confers lifelong immunity. Unlike dengue, there is only one serotype, so prior infection is believed to be fully protective against reinfection. This is one reason why areas with historically high attack rates (e.g., Indian Ocean islands post-2006) have not seen repeat large-scale epidemics in the same population cohorts.
- Does chikungunya rash look like measles?
- The rash can superficially resemble measles — a maculopapular (flat-and-raised), sometimes itchy eruption mainly on the trunk, face, and limbs. Key differences: chikungunya rash appears after fever onset (not concurrent), is accompanied by severe joint pain absent in measles, and lacks the cephalocaudal progression and Koplik spots of measles. Context (travel history, outbreak setting, vaccination status) is critical in differentiating the two.
- Can I donate blood after chikungunya?
- Most blood services recommend deferring donation for at least 28 days after symptom resolution. During acute illness, blood donation is not permitted due to viremia risk. Some countries extend the deferral period for returning travelers from epidemic areas. Check with your national blood service for current guidelines, as they vary.
- What should I tell my doctor after returning from a trip with joint pain?
- Always mention your travel history, specific countries visited, and dates. Your doctor needs to consider tropical arthropod-borne diseases (chikungunya, dengue, Zika) in addition to common causes of acute arthritis (gout, reactive arthritis, rheumatoid flare). RT-PCR is available through most reference labs in high-income countries for acute presentations within 7 days; serology (IgM/IgG) is used for later presentations.
Quick Prevention Checklist
- Apply DEET or picaridin repellent every 4–6 hours when outdoors in endemic regions
- Wear long-sleeved shirts and long pants in light colors during dawn/dusk hours
- Use permethrin-treated clothing and bed nets where air conditioning is unavailable
- Eliminate standing water around your home (flower pots, gutters, tires, buckets)
- Keep windows and doors closed or screened; use air conditioning if available
- If pregnant, take extra precautions — neonatal chikungunya from viremic delivery can be severe
- If ill: use paracetamol for fever, rest, hydrate; avoid aspirin and ibuprofen until dengue is excluded
- Seek emergency care for: high fever in infants, neurological symptoms, or any sign of severe dehydration
Summary
Chikungunya is a mosquito-borne viral disease causing severe joint pain that can persist for months. While rarely fatal, it causes substantial disability and economic impact. The 2023 FDA approval of the first chikungunya vaccine (Ixchiq) marks a milestone, though vector control and personal protection remain the primary prevention tools. Anyone traveling to endemic areas should take mosquito precautions seriously, and travelers returning with fever and joint pain should mention their travel history to their healthcare provider immediately.
Related: Dengue · Zika · India & Dengue
| Primary source | WHO GHO API |
| Source URL | https://www.who.int/news-room/fact-sheets/detail/chikungunya |
| Update frequency | Hourly fetch; WHO publishes periodically |
| Last checked | June 2025 |
| Limitation | Cases may be underreported. Data reflects official reports only. |